Editas Medicine (NASDAQ: EDIT) is researching the use of gene editing to treat disease. After the company updated investors on its progress on Aug. 9, shares soared 18.8% last month, according to S&P Global Market Intelligence.
Editas Medicine (NASDAQ: EDIT) is researching the use of gene editing to treat disease. After the company updated investors on its progress on Aug. 9, shares soared 18.8% last month, according to S&P Global Market Intelligence.